HLB affiliates, including HLB Group and HLB Pharm, are undergoing FDA review for a jointly developed combination therapy targeting liver cancer, alongside Elevar Therapeutics and Hengrui Pharmaceuticals.
1 report, 1 independent
Updated Jun 1
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
HLB affiliates, including HLB Group and HLB Pharm, are undergoing FDA review for a jointly developed combination therapy targeting liver cancer, alongside Elevar Therapeutics and Hengrui Pharmaceuticals.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
Related events
- Arise is seeking FDA approval for a drug as of October 7, 2026.
- Experimental therapies require approval from the FDA.
- Zenith collaborates with Harvard researchers on clinical studies, receiving FDA clearance for the trial.
- FDA is willing to review updated submissions, while biotech hubs leverage AI to ease clinical development bottlenecks.
- The FDA reviewed gene therapy applications and provided milestone payments for dosing involving Regenxbio and AbbVie.